Participants 163 200 4
patients with acute coronary syndrome
Participants 203 422 5
OBJECTIVES This study aimed to determine whether serial autologous infusions of selective high-density lipoprotein (HDL) delipidated plasma are feasible and well tolerated in patients with acute coronary syndrome (ACS).
Participants 644 859 5
METHODS ACS patients undergoing cardiac catheterization with >or=1 nonobstructive native coronary artery atheroma were randomized to either 7 weekly HDL selective delipidated or control plasma apheresis/reinfusions.
Participants 1657 1793 4
CONCLUSIONS In ACS patients, serial autologous infusions of selective HDL delipidated plasma are clinically feasible and well tolerated.
